Status:
COMPLETED
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
Lead Sponsor:
Alizyme
Conditions:
Irritable Bowel Syndrome
Eligibility:
FEMALE
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
Detailed Description
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by recurrent symptoms of abdominal pain/discomfort accompanied by disturbed bowel function. In this study female pa...
Eligibility Criteria
Inclusion
- Females with constipation predominant IBS as defined by the Rome II criteria
- Colonoscopy or sigmoidoscopy in previous 5 years showed no significant disease
Exclusion
- Patients who have diarrhoea predominant or alternating symptom IBS
- Other gastrointestinal diseases that affect bowel transit
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
1821 Patients enrolled
Trial Details
Trial ID
NCT00268879
Start Date
December 1 2005
End Date
January 1 2008
Last Update
February 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alizyme
Cambridge, United Kingdom